SG11201705889VA - Prevention or Treatment of Uratic or Gouty Diseases - Google Patents
Prevention or Treatment of Uratic or Gouty DiseasesInfo
- Publication number
- SG11201705889VA SG11201705889VA SG11201705889VA SG11201705889VA SG11201705889VA SG 11201705889V A SG11201705889V A SG 11201705889VA SG 11201705889V A SG11201705889V A SG 11201705889VA SG 11201705889V A SG11201705889V A SG 11201705889VA SG 11201705889V A SG11201705889V A SG 11201705889VA
- Authority
- SG
- Singapore
- Prior art keywords
- uratic
- prevention
- treatment
- gouty
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510048096 | 2015-01-30 | ||
| CN201510080714 | 2015-02-13 | ||
| CN201510079809 | 2015-02-13 | ||
| CN201510216089 | 2015-04-30 | ||
| PCT/CN2016/000061 WO2016119570A1 (en) | 2015-01-30 | 2016-01-28 | Prevention or treatment of uric acid or gout disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201705889VA true SG11201705889VA (en) | 2017-08-30 |
Family
ID=56542370
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201907026RA SG10201907026RA (en) | 2015-01-30 | 2016-01-28 | Prevention or Treatment of Uratic or Gouty Diseases |
| SG11201705889VA SG11201705889VA (en) | 2015-01-30 | 2016-01-28 | Prevention or Treatment of Uratic or Gouty Diseases |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201907026RA SG10201907026RA (en) | 2015-01-30 | 2016-01-28 | Prevention or Treatment of Uratic or Gouty Diseases |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10322132B2 (en) |
| EP (1) | EP3251675B1 (en) |
| JP (1) | JP6678685B2 (en) |
| KR (1) | KR102128810B1 (en) |
| CN (1) | CN107206002B (en) |
| AU (1) | AU2016212625B2 (en) |
| BR (1) | BR112017016065A2 (en) |
| CA (1) | CA2973746C (en) |
| CY (1) | CY1124383T1 (en) |
| DK (1) | DK3251675T3 (en) |
| EA (1) | EA034139B1 (en) |
| ES (1) | ES2881872T3 (en) |
| HK (2) | HK1244434A1 (en) |
| HR (1) | HRP20211007T1 (en) |
| HU (1) | HUE054741T2 (en) |
| IL (1) | IL253726B2 (en) |
| LT (1) | LT3251675T (en) |
| MA (1) | MA41431B1 (en) |
| MX (1) | MX2017009853A (en) |
| PL (1) | PL3251675T3 (en) |
| PT (1) | PT3251675T (en) |
| SG (2) | SG10201907026RA (en) |
| SI (1) | SI3251675T1 (en) |
| TW (1) | TWI680761B (en) |
| WO (1) | WO2016119570A1 (en) |
| ZA (1) | ZA201704600B (en) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8906792D0 (en) | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
| AU3725893A (en) | 1992-02-21 | 1993-09-13 | Smithkline Beecham Corporation | TNF inhibitors |
| AR015966A1 (en) | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | USE OF A PDE4 INHIBITOR COMPOUND FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR PRURITE TREATMENT |
| WO2005077950A2 (en) * | 2004-02-14 | 2005-08-25 | Smithkline Beecham Corporation | Medicaments with hm74a receptor activity |
| ES2355325T3 (en) * | 2006-06-23 | 2011-03-24 | Incyte Corporation | DERIVATIVES OF PURINONA AS AGONISTS OF HM74A. |
| WO2007150026A2 (en) * | 2006-06-23 | 2007-12-27 | Incyte Corporation | Purinone derivatives as hm74a agonists |
| WO2010071865A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
| US20110136835A1 (en) | 2009-09-14 | 2011-06-09 | Nuon Therapeutics, Inc. | Combination formulations of tranilast and allopurinol and methods related thereto |
| WO2011057110A1 (en) | 2009-11-06 | 2011-05-12 | Ruprecht-Karls-Universitat-Heidelberg | Gpr109a agonists for the treatment of cerebral ischemia |
-
2016
- 2016-01-28 SG SG10201907026RA patent/SG10201907026RA/en unknown
- 2016-01-28 BR BR112017016065-0A patent/BR112017016065A2/en not_active Application Discontinuation
- 2016-01-28 ES ES16742632T patent/ES2881872T3/en active Active
- 2016-01-28 SG SG11201705889VA patent/SG11201705889VA/en unknown
- 2016-01-28 WO PCT/CN2016/000061 patent/WO2016119570A1/en active Application Filing
- 2016-01-28 MA MA41431A patent/MA41431B1/en unknown
- 2016-01-28 SI SI201631264T patent/SI3251675T1/en unknown
- 2016-01-28 PL PL16742632T patent/PL3251675T3/en unknown
- 2016-01-28 MX MX2017009853A patent/MX2017009853A/en unknown
- 2016-01-28 EA EA201791714A patent/EA034139B1/en unknown
- 2016-01-28 HU HUE16742632A patent/HUE054741T2/en unknown
- 2016-01-28 CN CN201680001581.8A patent/CN107206002B/en active Active
- 2016-01-28 CA CA2973746A patent/CA2973746C/en active Active
- 2016-01-28 KR KR1020177024392A patent/KR102128810B1/en active IP Right Grant
- 2016-01-28 PT PT167426329T patent/PT3251675T/en unknown
- 2016-01-28 AU AU2016212625A patent/AU2016212625B2/en active Active
- 2016-01-28 LT LTEP16742632.9T patent/LT3251675T/en unknown
- 2016-01-28 JP JP2017558605A patent/JP6678685B2/en active Active
- 2016-01-28 EP EP16742632.9A patent/EP3251675B1/en active Active
- 2016-01-28 DK DK16742632.9T patent/DK3251675T3/en active
- 2016-01-28 US US15/512,412 patent/US10322132B2/en active Active
- 2016-01-29 TW TW105102935A patent/TWI680761B/en active
-
2017
- 2017-07-07 ZA ZA2017/04600A patent/ZA201704600B/en unknown
- 2017-07-30 IL IL253726A patent/IL253726B2/en unknown
-
2018
- 2018-03-21 HK HK18103914.7A patent/HK1244434A1/en unknown
- 2018-04-16 HK HK18104884.1A patent/HK1245146A1/en unknown
-
2021
- 2021-06-22 CY CY20211100551T patent/CY1124383T1/en unknown
- 2021-06-26 HR HRP20211007TT patent/HRP20211007T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202006746B (en) | Methods of treatment | |
| IL253945A0 (en) | Kdm1a inhibitors for the treatment of disease | |
| EP3142707A4 (en) | Methods and compositions for prevention or treatment of a disease | |
| EP3182989A4 (en) | Methods and compositions for the prevention and treatment of disease | |
| HK1258994A1 (en) | Methods for treatment of diseases | |
| HK1249865B (en) | Treatment of pain | |
| GB201516905D0 (en) | Treatment of Neurodegenerative diseases | |
| IL248210A0 (en) | Methods and compositions for the treatment of vascular malformation | |
| IL259710A (en) | Compositions and methods of treatment for mvid and related diseases | |
| IL250594A0 (en) | A composition for the treatment of neuropathies and/or neuropathic pain | |
| GB201515244D0 (en) | Treatment of inflammatory disease or condition | |
| HK1246271A1 (en) | Method for the synthesis of hydroxy-triglycerides and uses thereof for the prevention and treatment of diseases | |
| HK1243937A1 (en) | Methods of treating diseases | |
| EP3377062C0 (en) | Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases | |
| RS64273B1 (en) | Treatment of mitochondrial diseases | |
| GB201412010D0 (en) | Treatment of hypertransaminasemia | |
| SG11202005850VA (en) | Methods of treatment of hypertrigl yceridemia | |
| IL259381B (en) | Mirabegron for the treatment of retinal diseases | |
| GB201512139D0 (en) | Methods of treatment | |
| SG11201705889VA (en) | Prevention or Treatment of Uratic or Gouty Diseases | |
| GB201621398D0 (en) | Treatment of emt-associated disease | |
| GB201610906D0 (en) | Treatment of cardiovascular disease | |
| EP3223828A4 (en) | Methods for the treatment and prevention of asbestos-related diseases | |
| GB201501800D0 (en) | Treatment of medical conditions | |
| GB201504413D0 (en) | Treatment of disease |